



Nalbuphine added to intrathecal morphine in total knee arthroplasty; effect on postoperative analgesic requirements and morphine related side effects

Moustafa Abdelaziz Moustafa & Rabab Saber Saleh

To cite this article: Moustafa Abdelaziz Moustafa & Rabab Saber Saleh (2012) Nalbuphine added to intrathecal morphine in total knee arthroplasty; effect on postoperative analgesic requirements and morphine related side effects, Alexandria Journal of Medicine, 48:2, 175-178, DOI: [10.1016/j.ajme.2012.01.003](https://doi.org/10.1016/j.ajme.2012.01.003)

To link to this article: <https://doi.org/10.1016/j.ajme.2012.01.003>



© 2012 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights reserved.



Published online: 17 May 2019.



Submit your article to this journal [↗](#)



Article views: 35



View related articles [↗](#)



Citing articles: 4 View citing articles [↗](#)



ORIGINAL ARTICLE

Nalbuphine added to intrathecal morphine in total knee arthroplasty; effect on postoperative analgesic requirements and morphine related side effects

Moustafa Abdelaziz Moustafa *, Rabab Saber Saleh

Faculty of Medicine, Anaesthesia and Surgical Intensive Care, Alexandria, Egypt

Received 19 December 2011; accepted 29 January 2012

Available online 2 March 2012

KEYWORDS

Nalbuphine;
Intrathecal anaesthesia;
Morphine;
Knee;
Postoperative analgesia

Abstract *Introduction:* Intrathecal morphine is widely used for postoperative pain control in major orthopaedic surgery. However, its use is associated with frequent side effects.

Aim of the work: Aim of the work was to investigate the effects of intrathecal coadministration of nalbuphine with intrathecal morphine on morphine related side effects and postoperative analgesic requirements.

Methods: In this study, the intrathecal addition of 1 mg nalbuphine hydrochloride to a combination of 3 ml hyperbaric bupivacaine 0.5% and 0.2 mg morphine sulfate was tried in patients undergoing total knee arthroplasty.

Results: Patients who received intrathecal nalbuphine suffered significantly less than the control group from vomiting and pruritus meanwhile there was no effect on the postoperative analgesic requirements or the incidence of urinary retention. Intrathecal addition of nalbuphine to morphine decreased the opioid related side effects without affection of postoperative analgesia.

Abbreviations: ASA, American Society of Anesthesiologists; Mg, milligram; G, gauge; VAS, visual analogue scale; 1st, first; PaCO₂, arterial carbon dioxide tension; mmHg, millimeter mercury; SPSS, statistical package for social sciences; Hr, hour; SD, standard deviation; PCA, patient controlled analgesia.

* Corresponding author.

E-mail address: m.3abdelaziz@hotmail.com (M.A. Moustafa).

2090-5068 © 2012 Alexandria University Faculty of Medicine.
Production and hosting by Elsevier B.V. All rights reserved.

Peer review under responsibility of Alexandria University Faculty of Medicine.

doi:10.1016/j.ajme.2012.01.003



Production and hosting by Elsevier

Conclusions: The addition of nalbuphine to morphine intrathecally decreases the opioid related side effects without affection of postoperative analgesia. This combination can improve postoperative pain management in patients undergoing knee surgery under spinal anaesthesia.

© 2012 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights reserved.

1. Introduction

Prolonged postoperative pain control following major orthopaedic procedures may be achieved by the administration of a single dose of intrathecal morphine.¹ However, the use of intrathecal (IT) morphine may result in serious side effects e.g. pruritus, urinary retention, nausea and vomiting² and delayed respiratory depression.³ These side effects may lead to patient discomfort and prolonged hospital stay thus limiting the usefulness of IT morphine.⁴ Morphine binds most readily to the mu-opioid receptor and less well to the kappa-opioid receptor. So, the undesirable adverse events of morphine are thought to result from agonism at the mu-opioid receptor.⁵

Many drugs have been tried with morphine to potentiate its analgesic effects or to reduce the adverse events.⁶ Nalbuphine is a mixed opioid agonist-antagonist that acts mainly through kappa-opioid receptors, and it may attenuate mu-opioid-receptor related side effects.³ Moreover, recent studies suggested that the analgesic effects of morphine and nalbuphine may be additive.⁷

2. Aim of the work

Aim of the work was to investigate the effects of adding nalbuphine to intrathecal morphine on postoperative analgesic requirements and morphine related side effects.

3. Methods

The study protocol was approved by the Ethics Committee of the Faculty of Medicine, Alexandria University. A written consent was obtained from the patients for participation in the study. Sixty patients scheduled for total knee arthroplasty were selected and the following were the criteria of patients to be included in the study:

Age 50–70 years.

ASA class I–II.

Exclusion criteria included:

Patient's refusal to participate in the study.

Uncooperative patients.

Any contraindication to spinal anaesthesia such as coagulopathy or low fixed cardiac output states.

Any patient with a history of allergy to any of the study drugs.

Complete history was taken from the patients and all patients were subjected to thorough examination and routine laboratory investigations including base line arterial blood gas analysis. All patients were premedicated with oral midazolam 7.5 mg two hours before admission to the operative theatre. On admission, an intravenous line was inserted to all patients

and 1litre of Ringer lactate solution was transmitted as a preload. Standard monitoring in the form of 3 leads electrocardiograph, pulse oximetry and non-invasive arterial blood pressure were attached. All patients were then subjected to spinal anaesthesia with 25G spinal needle. They were divided randomly into two equal groups of 30 patients each as follows:

Group A: Thirty patients received intrathecal injection of 3 ml hyperbaric bupivacaine 0.5% + 0.2 mg morphine sulfate in a total volume of 4 ml.

Group B: Thirty patients received intrathecal injection of 3 ml hyperbaric bupivacaine 0.5% + 0.2 mg morphine sulfate + 1 mg nalbuphine hydrochloride in a total volume of 4 ml.

All patients received spinal anaesthesia in the sitting position at the L₂₋₃ intervertebral space with a 25G spinal needle without barbotage after proper disinfection and local anaesthesia at the site of injection.

At the end of the operation, patients were discharged to the post anaesthesia care unit where they were monitored for 24 h for the following:

Pulse rate using 3 leads electrocardiograph.

Oxygen saturation using pulse oximetry.

Non-invasive arterial blood pressure every 2 h.

Respiratory rate every 2 h.

PaCO₂ via arterial blood gas analysis every 4 h.

Pain was assessed using Visual analogue scale (VAS)⁸ every 2 h. Patients were given boluses of 30 mg ketorolac intravenously if VAS score > 4.

Incidence of complications.

Vomiting: was managed with 4 mg ondansetron.

Pruritus: was treated with 8 mg dexamethazone.

Urinary retention: was managed with warm compresses and urinary catheterization if needed.

3.1. Measurements

Pain assessment:

Visual analogue scale.

Time to first analgesic requirement.

Total dose of intravenous ketorolac given postoperatively.

Evidence of complications:

Respiratory depression evidenced by respiratory rate < 8 breaths / minute or PaCO₂ > 10 mm Hg of the base line value.

Nausea and vomiting: was assessed using a 3-point scale⁹ (0 = no nausea and vomiting, 1 = mild to moderate nausea or vomiting not needing treatment, and 2 = severe nausea or vomiting needing treatment).

Itching: incidence.

Urinary retention requiring urinary catheterization.

3.2. Statistical analysis

Statistical analysis was done using Statistical Package for Social Sciences (SPSS/version 17) software. The statistical test used was as follows: Arythematic mean and standard deviation. For categorized parameters, Chi square test was used, while for two groups, *t*-test was used for parametric data. The level of significance was 0.05.

4. Results

All patients completed the study thirty in each group. Patients' characteristics and surgical data of the two groups were not significantly different (Table 1). There was no significant difference between the groups with respect to the time of the first postoperative requirement of analgesia as well as the total dose of postoperative ketorolac consumed for pain relief (Table 2).

No evidence of respiratory depression was detected in any patient during the study period. Vomiting occurred significantly more frequently among patients in group A (16 out of 30) compared with patients in group B (8 out of 30); $p = 0.018$ (Table 3).

The incidence of itching was significantly reduced in group B (7 out of 30, 23.3%) relative to group A (15 out of 30, 50%; $p = 0.032$). No significant difference was detected as regards the incidence of urinary retention between the two groups (Table 3).

5. Discussion

In this study, the intrathecal combination of morphine and nalbuphine did not affect the postoperative analgesia or the total postoperative analgesic requirements. Otherwise, the incidence of morphine related side effects was reduced regarding postoperative vomiting and itching. Intrathecal morphine resulted in a moderate and clinically relevant increase in the incidence of nausea, vomiting, pruritus and urinary retention in the meta-analysis done by Gehling et al.¹⁰ Since morphine binds most readily to the mu-opioid receptor, and less well to the kappa-receptor, this implies that the undesirable side effects of morphine are likely related to the mu-opioid receptor.⁷ In a study of 5969 patients who received between 0.2 and 0.8 mg morphine intrathecally, Gwirtz and coworkers¹¹ described the side-effects and complications of intrathecal morphine. Without a control group they found nausea or vomiting in 25%, pruritus in 37% and respiratory depression

in 3% of their patients. Nortcliffe et al.¹² used 0.1 or 0.2 mg of spinal morphine for analgesia in caesarean delivery and observed 67% and 60% incidence rates of nausea and vomiting, respectively which is slightly higher than the incidence in the current study (53.3%). They also demonstrated that pruritus was the most frequent side effect of intrathecal morphine and the incidence (87%) was consistent with previous research.¹¹ Neuraxial opioid-induced pruritus is likely due to cephalad migration of neuraxial opioids to the medulla where the "itch center" is suggested to be located and where they interact with the trigeminal nucleus.¹³ In the study carried out by Hein et al.,¹⁴ the most common side effect of intrathecal morphine for labour analgesia was pruritus which was equally common in all groups including controls (58–61%). Pruritus is known to occur due to activation of mu-opioid and 5-hydroxytryptamine 3 receptors and non-nociceptive neurons in the medulla and dorsal horn of the spinal cord, particularly in trigeminal nerve distribution.¹⁵

For nalbuphine, in 1997, Parker and coworkers¹⁶ demonstrated that the combination of morphine and nalbuphine in patient-controlled epidural analgesia (PCA) resulted in a dose-dependent decrease in epidural morphine related side effects. The analgesic effects of nalbuphine are due to activation

Table 1 Demographic data of the studied sample.

	Group A	Group B	<i>P</i>
Age (years)			
Range	59–72	60–74	
Mean ± S.D.	61.9 ± 10.3	62.1 ± 12.9	0.428
Gender			
Male	9 (30.0%)	11 (36.7%)	0.25
Female	21 (70.0%)	19 (63.3%)	
Duration of operation (h)	2.0–3.5	2.0–3.25	
Range	2.95	2.58	0.366
Mean ± S.D.	0.82	0.76	

Table 2 Comparison between the two studied groups regarding time to 1st analgesia (hr) and total consumption of ketorolac (mg).

	Group A <i>N</i> = 30	Group B <i>N</i> = 30	<i>P</i>
<i>Time to 1st analgesia (hr)</i>			
Range	13.5–19	13.5–18.2	
Mean ± S.D.	16.17 ± 1.66	16.39 ± 1.37	0.286
<i>Total ketorolac (mg)</i>			
Range	0–60	0–60	0.122
Mean ± S.D.	19.00 ± 24.26	12.00 ± 21.72	

Table 3 Comparison between the two studied groups regarding complications.

	Group A		Group B		<i>P</i>
	<i>N</i> = 30		<i>N</i> = 30		
	No.	%	No.	%	
<i>Nausea & vomiting</i>					
0	14	46.7	22	73.3	0.018*
1	10	33.3	8	26.7	
2	6	20.0	0	0.0	
<i>Itching</i>					
Yes	15	50.0	7	23.3	
No	15	50.0	23	76.7	0.032*
<i>Urinary retention</i>					
Yes	9	30.0	5	16.7	0.22
No	21	70.0	25	83.3	

Nausea and vomiting: 0 = no nausea and vomiting, 1 = mild to moderate nausea or vomiting not needing treatment, 2 = severe nausea or vomiting needing treatment.

* *P* is significant.

of the kappa-opioid receptor, and nalbuphine also has the potential to attenuate the mu-opioid receptor related effects. When combining morphine and nalbuphine together, the analgesic effect from mu-opioid receptor decreases, but the analgesic effect from kappa opioid receptor increases. The reduction in the incidence of pruritus is the major benefit of combining morphine and nalbuphine in PCA. Opioid-related pruritus derives from agonism at the mu opioid receptor.¹⁷ Nalbuphine does not lead to pruritus and it can suppress morphine-related pruritus.⁷

Although nalbuphine antagonizes the effect of mu-opioid receptor, Yeh et al.¹⁸ did not find that the severity and incidence of nausea, vomiting, or requirement of antiemetics were less in patients receiving this drug. They explained that nausea and vomiting may result by other mechanisms such as the effect of pain on the vomiting centre, the residual effect of anaesthetics on the chemoreceptor trigger zone or the effect of surgery. Secondly, the types of surgery, the methods of anaesthesia and the population in their study were different from the studies which reported that nalbuphine can reduce the incidence of morphine-induced nausea and vomiting.

6. Conclusions

Intrathecal addition of nalbuphine to morphine decreases the opioid related side effects without affection of postoperative analgesia. This combination can improve postoperative pain management in patients undergoing knee surgery under spinal anaesthesia.

References

1. Chang FL, Ho ST, Sheen MJ. Efficacy of mirtazapine in preventing intrathecal morphine-induced nausea and vomiting after orthopaedic surgery*. *Anaesthesia* 2010;**65**(12):1206–11.
2. Goodarzi M, Narasimhan RR. The effect of large-dose intrathecal opioids on the autonomic nervous system. *Anesth Analg* 2001;**93**(2):456–9.
3. Cole PJ, Craske DA, Wheartley RG. Efficacy and respiratory effects of low-dose spinal morphine for post-operative analgesia following knee arthroplasty. *Br J Anaesth* 2000;**85**(2):233–7.
4. Terajima K, Onodera H, Kobayashi M. Efficacy of intrathecal morphine for analgesia following elective cesarean section: comparison with previous delivery. *J Nippon Med Sch* 2003;**70**:327–33.
5. Gunion MK, Marchionine AM, Anderson CTM. Use of the mixed agonist–antagonist nalbuphine in opioid based analgesia. *Acute Pain* 2004;**6**:29–39.
6. Michelet P, Guervilly C, Helaine A. Adding ketamine to morphine for patient-controlled analgesia after thoracic surgery: influence on morphine consumption, respiratory function, and nocturnal desaturation. *Br J Anaesth* 2007;**99**:396–403.
7. Yeh YC, Lin TF, Chang HC, Chan WS, Wang YP, Lin CJ, et al. Combination of low-dose nalbuphine and morphine in patient-controlled analgesia decreases incidence of opioid-related side effects. *J Formos Med Assoc* 2009;**108**(7):548–53.
8. Bosshart H. Morphine and cancer progression: hydrogen peroxide points to need for more research. *J Opioid Manag* 2011;**7**(2):93–6.
9. Yazigi A, Chalhoub V, Madi-Jebara S, Haddad F, Hayek G. Prophylactic ondansetron is effective in the treatment of nausea and vomiting but not on pruritus after cesarean delivery with intrathecal sufentanil-morphine. *J Clin Anesth* 2002;**14**:183–6.
10. Gehling M, Tryba M. Risks and side-effects of intrathecal morphine combined with spinal anaesthesia: a meta-analysis. *Anaesthesia* 2009;**64**:643–51.
11. Gwirtz KH, Young JV, Byers RS. Safety and efficacy of intrathecal opioid analgesia for acute postoperative pain. *Anesth Analg* 1999;**88**:599–604.
12. Nortcliffe SA, Shah J, Buggy DJ. Prevention of postoperative nausea and vomiting after spinal morphine for caesarean section: comparison of cyclizine, dexamethasone and placebo. *Br J Anaesth* 2003;**90**:665–70.
13. Chaney MA. Side effects of intrathecal and epidural opioids. *Can J Anaesth* 1995;**42**:891–903.
14. Hein A, Rosblad P, Norman M, Ryniak S, Tingaker B, Jakobsson J, et al. Addition of low-dose morphine to intrathecal bupivacaine/sufentanil labour analgesia: a randomized controlled study. *Int J Obst Anesth* 2010;**19**:384–9.
15. Siddik-Sayyid SM, Aouad MT, Taha SK. Does ondansetron or granisetron prevent subarachnoid morphine-induced pruritus after cesarean delivery? *Anesth Analg* 2007;**104**:421–4.
16. Parker RK, Holtmann B, White PF. Patient-controlled epidural analgesia: interactions between nalbuphine and hydromorphone. *Anesth Analg* 1997;**84**:757–63.
17. Thomas DA, Hammond DL. Micro injection of morphine into the rat medullary dorsal horn produces a dose-dependent increase in facial scratching. *Brain Res* 1995;**695**:267–70.
18. Yeh YC, Lin TF, Lin FS, Wang YP, Lin CJ, Sun WZ. Combination of opioid agonist and agonist–antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain. *Br J Anaesth* 2008;**101**:542–8.